Replies to post #120303 on Biotech Values

[investorgold2002]

you maybe right. but FDA decision is likely in favor of panel vote most of the times??


"Amarin Corp., a Dublin-based biotechnology company developing a competing medicine for high cholesterol, may see a “small positive” from a change to TriLipix’s prescribing information, said Joseph Schwartz, an analyst at Leerink Swann in Boston, in an April 26 note to clients. Amarin’s drug AMR101 has a “pristine safety and tolerability profile” and may be submitted this year for FDA approval, Schwartz said. "


Happy with this data

http://ih.advfn.com/p.php?pid=nmona&article=47750706